Lightstone Value Plus REIT II, Inc. (LVPR)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Property, Plant & Equipment	136.14	137.82	142.8	180.09	215.18	225.07
Cash & Equivalents	23.89	27.14	36.19	42.23	15.13	15.35
Accounts Receivable	3.36	2.65	3.19	4.81	3.87	2.84
Investment In Debt and Equity Securities	10.23	10.21	9.29	4.19	6.78	6.9
Restricted Cash	4.99	4.94	4.55	0.33	1.83	3.08
Other Long-Term Assets	10.74	11.15	13.42	13.79	17.96	15.36
Total Assets	189.35	193.9	209.44	245.44	260.74	268.59
Long-Term Debt	101.27	101.18	100.82	118.18	139.91	139.74
Accounts Payable	7.43	6.49	6.87	7.98	6.53	7.86
Other Current Liabilities	1.56	1.57	1.64	0.46	0.54	0.62
Total Liabilities	110.27	109.24	109.33	126.62	149.27	150.82
Common Stock	0.16	0.16	0.17	0.17	0.17	0.17
Additional Paid-In Capital	136.8	137.41	143.22	144.97	146.31	147.1
Retained Earnings	-68.73	-63.96	-54.28	-37.66	-46.51	-41.19
Comprehensive Income & Other	-	-	-	0.01	-	0.08
Total Common Equity	68.23	73.61	89.1	107.49	99.98	106.17
Minority Interest	10.86	11.05	11.01	11.34	11.49	11.6
Shareholders' Equity	79.08	84.66	100.11	118.82	111.47	117.77
Total Liabilities & Equity	189.35	193.9	209.44	245.44	260.74	268.59
Total Debt	101.27	101.18	100.82	118.18	142.21	142.34
Net Cash (Debt)	-77.39	-74.04	-64.63	-75.95	-127.08	-126.99
Net Cash Per Share	-4.78	-4.52	-3.78	-4.41	-7.30	-7.28
Filing Date Shares Outstanding	16	16	16.5	17.17	17.2	17.4
Total Common Shares Outstanding	16.05	16.1	17	17.17	17.3	17.43
Book Value Per Share	4.25	4.57	5.24	6.26	5.78	6.09
Tangible Book Value	68.23	73.61	89.1	107.49	99.98	106.17
Tangible Book Value Per Share	4.25	4.57	5.24	6.26	5.78	6.09
Land	26.18	26.18	26.15	32.21	36.71	36.69
Buildings	144.88	146.46	146.13	177.55	203.66	203.56
Construction In Progress	0.69	0.23	0.13	0.13	0.12	0.08

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.